Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab and CAPEOX with Short-course Radiation for Ultra Low Rectal Adenocarcinoma
NCT06266832Phase 2Recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of adebrelimab in rectal adenocarcinoma, sponsored by Sir Run-Run Shaw Hospital. Started Jan 2024; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT06266832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06266832.